home / stock / vktx / vktx articles

VKTX Articles, Viking Therapeutics Inc.

Stock Information
Company Name: Viking Therapeutics Inc.
Stock Symbol: VKTX
Market: NASDAQ
Website: vikingtherapeutics.com
Menu
VKTX VKTX Quote VKTX Short VKTX News VKTX Articles VKTX Message Board
Get VKTX Alerts

News, Short Squeeze, Breakout and More Instantly...
Obesity-Drugs Focused Stocks Tumble On Wednesday - What's Going On With Eli Lilly, Novo Nordisk, Viking Therapeutics, Structure Therapeutics? | Benzinga

Eli Lilly And Co (NYSE:LLY), Novo Nordisk A/S (NYSE:NVO), Viking Therapeutics Inc (NASDAQ:VKTX), and Structure Therapeutics Inc (NASDAQ:GPCR) stock...
Jim Cramer Says Don't Sell Match Group: 'You've Just Got A Very, Very Smart Investor In There' | Benzinga

On CNBC's “Mad Money Lightning Round,” Jim Cramer said Fortinet, Inc. (NASDAQ:FTNT) is not his favorite. He added that we own Palo...

$100 Invested In This Stock 5 Years Ago Would Be Worth $600 Today | Benzinga

Viking Therapeutics (NASDAQ:VKTX) has outperformed the market over the past 5 years by 31.7% on an annualized basis producing an average annual ret...

What's Going On With Fattly Liver Disease Focused Madrigal Pharmaceuticals, Sagimet Biosciences Shares On Wednesday? | Benzinga

On Wednesday, the stocks of Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) and Sagimet Biosciences Inc (NASDAQ:SGMT) are trading lower. At the EASL Int...
What's Going On With Viking Therapeutics Stock On Tuesday? | Benzinga

Viking Therapeutics Inc (NASDAQ:VKTX) released 52-week histologic data from its Phase 2b VOYAGE study of VK2809 in patients with biopsy-confirmed...

4 Stocks That Could Break Novo Nordisk, Lilly's Obesity Duopoly | Benzinga

The obesity market has garnered much interest lately, ever since Novo Nordisk (NYSE: NVO) received FDA approval for its obesity drug Wegovy in 2021...

Should You Hold Viking Therapeutics in Your Portfolio? | Benzinga

Viking Therapeutics (NASDAQ: VKTX), a clinical-stage company focused on developing novel therapeutics for metabolic and endocrine disorders, has be...
Here's How Much You Would Have Made Owning Viking Therapeutics Stock In The Last 5 Years | Benzinga

Viking Therapeutics (NASDAQ:VKTX) has outperformed the market over the past 5 years by 44.59% on an annualized basis producing an average annual re...

Viking Therapeutics Reports Q1 Results: 'An Exceptional Period' Says CEO | Benzinga

Viking Therapeutics, Inc. (NASDAQ:VKTX) reported its first-quarter financial results after the bell Wednesday. Here's a look at the highlights...

$100 Invested In Viking Therapeutics 5 Years Ago Would Be Worth This Much Today | Benzinga

Viking Therapeutics (NASDAQ:VKTX) has outperformed the market over the past 5 years by 38.64% on an annualized basis producing an average annual re...
Next 10